Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

  • Technology appraisal guidance
  • TA287
  • Published: 

History

Background information

Pulmonary embolism (acute treatment, VTE prevention): rivaroxaban equality impact assessment - guidance review

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: final appraisal determination

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: appendix B - Final scope

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: appendix C - Final matrix

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: appendix D - scope consultation comments table

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: equality impact assessment form

Pulmonary embolism (acute treatment, VTE prevention - rivaroxaban: appendix A draft scope for consultation (post referral) October 2012

Pulmonary embolism (acute treatment, VTE prevention - rivaroxaban: appendix B draft matrix for consultation (post referral) October 2012

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: appendix B - draft scope for consultation (pre-referral) August 2010

Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban: appendix C - provisional matrix (pre-referral) August 2010